Objective To evaluate the clinical efficacy of EGFR-TKI ( erlotinib and gefitinib) for brain me-tastases in non-small cell lung cancer patents with EGFR mutation. Methods A total of 73 brain metastases patients of pulmonary adenocarcinoma with EGFR mutation were retrospectively analyzed, and all of them were treated with o-ral erlotinib (150mg/d, 39 patients) or gefitinib (250mg/d, 34 patients). The treatment would be stopped when the intracranial disease progressed or death, intolerable side effect or uncontrolled new lesions appeared. Results The response rate ( RR ) and disease control rate ( DCR ) of intracranial disease were 51. 3%, 94. 9% and 53. 0%, 94. 1% in the two groups respectively (P=0. 861). The RR and DCR of extracranial disease were 59. 0%, 97. 4%and 50. 0%, 97. 1% in both groups respectively (P=0. 793). The median progression free survival (PFS) and o-verall survival time (OS) were 11. 3 months and 15. 1 months vs 12. 1 months and 16. 4 months (P=0. 913, P=0. 641) in the two groups. There was little side effect, which could all be tolerated. Conclusion EGFR-TKI shows significant effect on brain metastases in NSCLC patients with EGFR mutation, and it can be used as the first-line or second-line treatment with less toxicity. Erlotinib and gefitinib show no difference in prognosis of patients.%目的：探讨EFGR-TKI(厄洛替尼与吉非替尼)治疗非小细胞肺癌( NSCLC) EGFR突变阳性脑转移患者的临床疗效。方法回顾收集分析我科73例EGFR突变阳性的肺腺癌脑转移患者的临床病历资料,患者均口服厄洛替尼150mg/d(39例)或吉非替尼250 mg/d(34例),服药直至患者颅内外病情进展、死亡、出现不可耐受的副反应或不能控制的新发病灶。结果厄洛替尼组与吉非替尼组颅内病变的有效率(RR)和疾病控制率(DCR)分别为51．3%,94．9%和53．0%,94．1%(P=0．861),两组颅外病变的有效率和疾病控制率分别为59．0%,97．4%和50．0%,97．1%(P=0．793),两组患者的中位无进展生存期(PFS)和总生存期(OS)分别为11．3个月和15．1个月vs12．1个月和16．4个月(P=0．913,P=0．641)。两种药物的副反应均较小,患者都可以耐受。结论 EGFR-TKI对EGFR突变阳性的NSCLC脑转移均具有较好地疗效,可作为EGFR突变阳性脑转移患者的一线或二线治疗,药物副反应较小,两种药物对患者的预后无明显差异。
展开▼
